146 related articles for article (PubMed ID: 8228734)
1. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
[TBL] [Abstract][Full Text] [Related]
2. Effects of an orally active vasopressin V1 receptor antagonist.
Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
[TBL] [Abstract][Full Text] [Related]
4. Vascular responses to vasopressin antagonists in man and rat.
Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
[TBL] [Abstract][Full Text] [Related]
5. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M
Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555
[TBL] [Abstract][Full Text] [Related]
6. Human internal mammary artery responses to non-peptide vasopressin antagonists.
Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI
Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263
[TBL] [Abstract][Full Text] [Related]
7. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
[TBL] [Abstract][Full Text] [Related]
8. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
[TBL] [Abstract][Full Text] [Related]
9. Effect of a new V1 antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells.
Okada K; Ishikawa S; Saito T
Biochem Biophys Res Commun; 1991 Jul; 178(2):707-12. PubMed ID: 1650196
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
Yamamura Y; Ogawa H; Yamashita H; Chihara T; Miyamoto H; Nakamura S; Onogawa T; Yamashita T; Hosokawa T; Mori T
Br J Pharmacol; 1992 Apr; 105(4):787-91. PubMed ID: 1387020
[TBL] [Abstract][Full Text] [Related]
11. [3H]desGly-NH2(9)-d(CH2)5[D-Ileu2,Ileu4]AVP: an AVP V2 receptor antagonist radioligand.
Trinder D; Stephenson JM; Gao X; Phillips PA; Risvanis J; Johnston CI
Peptides; 1991; 12(6):1195-200. PubMed ID: 1815207
[TBL] [Abstract][Full Text] [Related]
12. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.
Ogawa H; Yamamura Y; Miyamoto H; Kondo K; Yamashita H; Nakaya K; Chihara T; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1993 Jul; 36(14):2011-7. PubMed ID: 8393113
[TBL] [Abstract][Full Text] [Related]
13. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
14. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
[TBL] [Abstract][Full Text] [Related]
16. OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog.
Chihara T; Nakamura S; Onogawa T; Yamashita T; Yamamura Y; Mori T; Tominaga M; Yabuuchi Y
Jpn J Pharmacol; 1995 Jul; 68(3):345-7. PubMed ID: 7474558
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268.
Li X; Kribben A; Wieder ED; Tsai P; Nemenoff RA; Schrier RW
Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632
[TBL] [Abstract][Full Text] [Related]
18. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260.
Mimura Y; Ogura T; Hayakawa N; Otsuka F; Hashimoto M; Yamauchi T; Makino H; Ogawa N
Nephron; 1997; 76(3):331-6. PubMed ID: 9226235
[TBL] [Abstract][Full Text] [Related]
19. Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries.
Chiba S; Tsukada M
Eur J Pharmacol; 1992 Oct; 221(2-3):393-5. PubMed ID: 1330628
[TBL] [Abstract][Full Text] [Related]
20. Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium.
Atke A; Vilhardt H; Hauzerova L; Barth T; Andersen LF
Eur J Pharmacol; 1995 Jul; 281(1):63-8. PubMed ID: 8566118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
